( -48% 180 88 -51% 283 2...)Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC,Health

-48% 180 88 -51% 283 201 -29% LDL-C 651 328 -50% 197 91 -54% 445 301 -32% VLDL-C 18 12 -33% 33 23 -29% 30 21 -30% Non-HDL 669 340 -49% 230 114 -50% 475 322 -32% HDL-C 27 37 40% 29 30 5% 27 29 7% ApoA-1 86 95 10% 109 106 -2% 89 89 1% TC 695 377 -46% 258 144 -44% 502 351 -30% TG 90 60 -33% 163 115 -29% 151 104 -31% Lp(a) 104 48 -54% 140 112 -20% 108 87 -19% Presentation Details Date: Monday, March 26, 2007 Session: 603: Common Challenges in Preventive Cardiology (7:00 - 8:30 a.m. CT) Track: ACC.Symposium Room: Auditorium B Presentation: 603-8 Time: 8:15 - 8:30 a.m. Speaker: Dr. Evan A. Stein Title: High Low-Density Lipoprotein Cholesterol on Three Drugs More about Phase 2 Trials for ISIS 301012

Additional data from two ongoing studies in polygenic hypercholesterolemia will be presented at the ACC. Results of a study in which patients treated with up to 400 mg/week of ISIS 301012 as a single agent for three months were reported yesterday in a poster session, and results of a study in which patients were treated with up to 400 mg/week of ISIS 301012 added to stable statin therapy for five weeks will be presented in an oral session later today. Extended three-month treatment periods are planned for subsequent cohorts of 200 and 300 mg/week doses in the statin coadministration study, to be reported later in the year. Also later in the year, results from an ongoing double-blind, placebo-controlled, dose-escalation study in patients with heterozygous FH will be reported.

About Familial Hypercholesterolemia

'"/>

Page: 1 2 3 4 5 6
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA